INTRODUCTION

MULTIPLE LINES OF EVIDENCE SUGGEST A FUNCTION-AL INTERACTION BETWEEN ADENOSINE AND OPIOIDS IN THE MODULATION OF NOCICEPTION AND SLEEP.
Adenosine is a purine formed from adenosine monophosphate (AMP) and adenosine receptor activation can alter the response to nociceptive stimuli. 1, 2 Endogenous purinergic systems also can induce antinociception 3 and enhance antinociception produced by opioids. 4, 5 Thus, adenosine can serve as a secondary neuromodulator of mu opioid mediated antinociception. 6 Opioids, when given in analgesic doses to healthy volunteers or opioid addicts, increase the number of wake episodes, suppress non rapid eye movement (NREM) sleep, and often abolish rapid eye movement (REM) sleep. 7 The nature and time course of postoperative disruption of sleep can be accounted for, in part, by opioid administration. 8 The cellular and molecular mechanisms underlying the unwanted side effects of opioids, such as inhibition of REM sleep, 9,10 remain incompletely understood, and encourage the development of pharmacological adjuncts to opioid therapy. For example, systemic adenosine infusion during inhalation anesthesia can be analgesic and eliminate respiratory depression. 11 In contrast to opioids, which disrupt the sleep cycle, 9,12,13 adenosine promotes sleep. [14] [15] [16] [17] [18] [19] [20] [21] [22] Evidence in support of adenosine as an endogenous sleep promoting substance includes the findings that brain levels of adenosine increase during prolonged wakefulness 22, 23 and that pontine delivery of adenosine increases sleep in cat 21 and rat. 24 Thus, it is appealing to consider the possibility of adjunct adenosine administration with opioids to achieve satisfactory pain control and concomitant elimination of opioid-induced sleep disruption.
Opioid-adenosine interactions might occur at the signal transduction level because opioid 25 and adenosine 26 receptors are G protein coupled. Therefore, the present study used in vitro Study Objectives: Opioids delivered to the pons inhibit REM sleep, whereas pontine administration of adenosine enhances REM sleep. In other brain areas opioids and adenosine interact to produce antinociception. Adenosine A 1 receptors and mu opioid receptors each activate G i /G o proteins. This study tested the hypothesis that combined treatment with the adenosine A 1 receptor agonist SPA and the mu opioid agonist DAMGO would enhance G protein activation to a greater level than produced by either agonist alone. G protein activation was quantified in seven brainstem regions regulating sleep and nociception. This study also tested the hypothesis that G protein activation caused by SPA would be concentration dependent and blocked by the adenosine A 1 receptor antagonist DPCPX. Design: Activation of G proteins was assessed autoradiographically by agonist stimulation of [ 35 S]GTPγS binding in slide-mounted sections of rat brainstem. G protein activation was quantified in nCi/g tissue for pontine reticular formation, dorsal raphe, ventrolateral and dorsomedial periaqueductal gray, and laterodorsal and pedunculopontine tegmental nuclei. 
Setting: N/A [ 35 S]guanylyl-5'-O-(γ-thio)-triphosphate ([ 35
S]GTPγS) binding in rat brainstem to test the hypothesis that combined tissue treatment with the A 1 receptor agonist N 6 -p-sulphophenyladenosine
Tissue preparation and G protein assay
Rats were decapitated in accordance with the guidelines of the National Institutes of Health (Guide for the Care and Use of Laboratory Animals, 7th ed., National Academy of Sciences Press, Washington, DC, 1996). Brains were removed quickly and frozen in an isopentane/bromobutane bilayer (-30 o C). Brainstems were cut serially as 20 µm coronal sections on a Hacker Bright cryostat (Fairfield, NJ). Two sections were thaw mounted onto each gelatin coated glass slide. Brainstem sections were cut from caudal to rostral and saved from approximately Bregma -10.30 mm to Bregma -7.30 mm. 28 These sections included the following seven regions known to contribute to the regulation of sleep and nociceptive processing: 29 pontine reticular nucleus, caudal part (PnC), pontine reticular nucleus, oral part (PnO), dorsal raphe nucleus (DR), laterodorsal tegmental nucleus (LDT), pedunculopontine tegmental nucleus (PPT), ventrolateral periaqueductal gray (VLPAG), and dorsomedial periaqueductal gray (DMPAG). Slide mounted tissue sections were dried in a vacuum desiccator on ice for two hours, then stored at -70 o C until assayed.
On the day of the assay, tissue sections were brought to room temperature and sorted serially. The sorting process consisted of assigning each slide to one of eight assay conditions. Assignments were made sequentially and when the eighth slide was assigned to the eighth assay condition, the serial assignment was reset to place the ninth slide in assay Condition 1. This tissue sorting scheme made it possible for all seven brainstem regions of interest to be treated with each of the eight assay conditions.
The in vitro [ 35 S]GTPγS autoradiography assay has been described previously. [30] [31] [32] [33] Briefly, all tissue sections were presoaked in assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 100 mM NaCl, 0.2 mM EGTA, pH 7.4) for 10 minutes at room temperature (25 o C). All sections then were preincubated for 15 minutes in the same assay buffer containing 2 mM GDP. Following this preincubation step, the eight assay conditions were differentiated as follows. In a separate series of experiments, the effect of increasing concentrations of SPA (0.1 µM, 1 µM, 10 µM, 100 µM, and 1 mM) on G protein activation was determined. The two-hour incubation step for all eight assay conditions and for the concentration response study was followed by two rinses with cold (4 o C) Tris-HCl for two minutes each, then one rinse with cold, deionized H 2 O for 30 seconds. The rinses completed the G protein assay. Brain sections then were dried under a room temperature stream of air for 10 minutes and placed in a room temperature vacuum desiccator overnight.
The next day, assayed tissue sections were placed in lightproof cassettes with 14 C Microscale standards (31-883 nCi/g, Amersham, Arlington Heights, IL) and Reflection autoradiography film. Tissue sections and standards were exposed to film for 72 hours and the films were developed using a Kodak M35A X-OMAT autoprocessor. Tissue sections then were fixed with paraformaldehyde vapors at 80 o C 35 and stained with cresyl violet to aid in the localization of DR, PnO, PnC, LDT, PPT, DMPAG, and VLPAG.
Image analysis and statistics
All autoradiographic images and the cresyl violet stained sections used to generate those autoradiographic images were backlit with a Northern Light Illuminator (Imaging Research, St. Catherines, Ontario, Canada) and digitized using a Cohu (San Diego, CA) CCD camera connected to a Micro Nikon 60 mm objective. Digitized images were analyzed using the ScionImage 1.62c version of NIH Image and a G3 Apple Macintosh comput- er. Each of the seven brainstem regions studied, first was identified on the cresyl violet stained image using a rat brain atlas. 28 Each brainstem region was outlined on the digitized cresyl violet stained image and the contour was transferred to the matching autoradiographic image for quantification of optical density within that region. This procedure insured that the boundaries of brainstem regions were identified according to well-defined histological criteria. 28 Optical density measurements were converted to nCi/g of tissue using a correction factor for the 14 C standards. 30, 31 For each rat, the number of optical density measurements (n) obtained per brainstem region depended upon the rostral to caudal extent of that nucleus. Sample sizes (n) are reported in the figure legends. Mean NSB values for each brainstem region were subtracted from total binding values. Results are reported as percent change from basal [ 35 S]GTPγS binding. As in previous studies 30, 31 analysis of variance (ANOVA) and TukeyKramer multiple comparison test were used to evaluate significant (p<0.05) changes in G protein activation.
Quantitative determination of G protein interactions
The goal of the analysis described here was to determine if G protein activation by combined treatment with two agonists was fully additive, non-additive, or partially additive. 36, 37 The amount of G protein activation produced by treatment with SPA alone, DAMGO alone, and combined treatment with SPA and DAMGO (SPA+DAMGO) was determined experimentally, as described above. The sum (∑) of G protein activation produced by treatment with SPA alone or DAMGO alone (∑(SPA+DAMGO)) was determined arithmetically. Analysis of variance, Tukey-Kramer, and t-test were used to make the following two comparisons: 1) The arithmetic sum of G protein activation produced by either agonist alone (∑(SPA+DAMGO)) was compared to the amount of G protein activation produced by combined agonist treatment (SPA+DAMGO); and 2) G protein activation produced by combined agonist treatment (SPA+DAMGO) was compared to the amount of G protein activation produced by SPA alone and DAMGO alone. A demonstration of full additivity required that the sum of G protein acti- vation produced by treatment with SPA alone or DAMGO alone (∑(SPA+DAMGO)) be equal to the amount of G protein activation produced by combined treatment with SPA+DAMGO. Thus, full additivity was defined by the relationship ∑(SPA+DAMGO) = SPA+DAMGO. A demonstration of nonadditivity required that the amount of G protein activation produced by combined treatment with SPA and DAMGO (SPA+DAMGO) be equal to the amount of G protein activation produced by treatment with SPA alone or DAMGO alone. Thus, non-additivity was defined by the relationship SPA+DAMGO = SPA alone or DAMGO alone. A demonstration of partial additivity had two requirements. The first requirement was that the amount of G protein activation produced by combined treatment with SPA and DAMGO (SPA+DAMGO) be significantly (p<0.05) greater that the amount of G protein activation produced by treatment with either SPA alone or DAMGO alone. The second requirement was that the amount of G protein activation produced by combined treatment with SPA and DAMGO (SPA+DAMGO) be significantly (p<0.05) less than the sum of G protein activation produced by treatment with SPA alone and DAMGO alone (∑(SPA+DAMGO)). Thus, partial additivity was defined by the relationship SPA alone or DAMGO < SPA+DAMGO < ∑(SPA+DAMGO).
RESULTS
Combined treatment with the adenosine A 1 agonist (SPA) and the mu opioid agonist (DAMGO) activated G proteins in a partially additive manner. Figure 1 illustrates the distribution of mu opioid-and adenosine A 1 receptor-stimulated [ 35 S]GTPγS binding in brainstem regions shown by functional studies to modulate nociception and sleep. These color-coded autoradiograms exemplify G protein activation by SPA and DAMGO relative to control (basal). The autoradiographic data consistently revealed two key features. First, G protein activation by SPA alone and DAMGO alone was heterogeneous within the brainstem and corresponded to regions known to contain adenosine 38 and opioid 39 receptors, respectively. Second, combined treatment with SPA+DAMGO caused greater activation of G proteins than treatment with DAMGO alone or SPA alone. These observations encouraged a quantitative comparison of G protein activation within brainstem regions across assay conditions.
Data from many laboratories concur that brainstem nuclei including PnC, PnO, LDT, PPT, and DR play a key role in the regulation of sleep and wakefulness. 29, 40 For each of these nuclei, ANOVA revealed a statistically significant effect of assay condition on G protein activation. The sum of G protein activation produced by treatment with DAMGO alone and SPA alone (solid bars, ∑(SPA+DAMGO)) was significantly greater than the amount of G protein activation produced by combined treatment with SPA+DAMGO (cross, p<0.01, solid bar vs. crosshatched bar). DMPAG VLPAG (SPA+DAMGO) had been fully additive. 36, 37 Three findings are summarized by Figure 2 . First, treatment with SPA alone or DAMGO alone significantly increased G protein activation over basal levels. Second, combined treatment with SPA+DAMGO caused significantly greater G protein activation than either SPA alone or DAMGO alone. This finding indicates an additive effect of SPA+DAMGO on G protein activation. Third, the arithmetic sum (∑) of G protein activation produced by SPA alone and DAMGO alone (∑(SPA+DAMGO)) was significantly greater than the amount of G protein activation produced by combined treatment with SPA+DAMGO (Fig. 2 , solid bars vs. crosshatched bars). This finding indicates that the effect on G protein activation of combined treatment with an adenosine A 1 agonist and a mu opioid agonist was partially additive for the five brainstem regions shown in Figure 2 .
Considerable data indicate that the periaqueductal gray is involved in the processing of nociceptive input. 41 Figure 3 summarizes three results for DMPAG and VLPAG. First, treatment with SPA alone or DAMGO alone significantly increased G protein activation over basal levels. Second, combined treatment with SPA+DAMGO significantly increased G protein activation above levels caused by SPA alone or DAMGO alone. Third, combined treatment with SPA+DAMGO caused less G protein activation than would have been expected from a fully additive response (Fig. 3 , crosshatched bars vs. solid bars). Thus, combined agonist treatment produced a partially additive activation of G proteins in DMPAG and VLPAG.
Brain region differences in amount of G protein activation by combined treatment with SPA + DAMGO. Data in Figures 2 and 3 show that for the seven brainstem regions studied, combined treatment with an adenosine A 1 receptor agonist (SPA) and a mu opioid receptor agonist (DAMGO) caused G protein activation that was partially additive. The next analysis compared the relative amounts of additivity found in the seven brainstem regions. Figure 4 shows the difference between the percent increase in G protein activation produced by combined treatment with SPA+DAMGO and the percent increase in G protein activation produced by summing the effects of treatment with SPA alone and DAMGO alone (∑(SPA+DAMGO)). Fig. 4 plots the difference between the calculated fully additive response (solid bars in Figs. 2 and 3 ) and the observed partially additive response (crosshatched bars in Figs. 2 and 3) for each brainstem region. The Fig. 4 data reveal that the smallest difference between partial and full additivity occurred in the dorsal raphe nucleus (DR) and the greatest difference between partial and full additivity occurred in the pedunculopontine tegmental nucleus (PPT). The show that combined treatment with SPA plus DPCPX returned binding to control (left column) levels. Pharmacological antagonism of SPA-induced G protein activation was assessed quantitatively using brainstem sections from three rats. Optical density measurements (n) from PnC (n=135), PnO (n=132), DR (n=62), LDT (n=102), PPT (n=69), DMPAG (n=53), and VLPAG (n=93) showed that SPA-induced G protein activation was significantly (p<0.001) blocked by DPCPX in all seven brainstem regions.
Effects of endogenous adenosine on basal [ 35 S]GTPγ γS binding.
To determine whether endogenous adenosine accounted for a portion of basal G protein binding, tissue sections from three rats were treated with either the adenosine A 1 receptor antagonist DPCPX alone, or the degradative enzyme ADA alone. Optical density measurements (n) showed that neither DPCPX nor ADA significantly altered basal binding in DR (n=72), LDT (n=107), PPT (n=67), DMPAG (n=52), and VLPAG (n=79). Optical density measurements (n) from PnC (n=153) and PnO (n=132) revealed that DPCPX and ADA each significantly (p<0.001) decreased [ 35 S]GTPγS binding below basal levels in these two pontine reticular formation areas.
G protein activation by the adenosine A 1 receptor agonist (SPA) was concentration dependent. Concentration response studies were designed as a further test of the hypothesis that G protein activation was receptor mediated. [ 35 S]GTPγS binding in DR, PnO, and PnC was quantified following treatment with five concentrations of SPA ranging from 10 -7 to 10 -3 M. Figure 6 shows that SPA stimulated [ 35 S]GTPγS binding in a concentration dependent manner. Following the evidence for anatomical site specificity (Figs. 1-3 ) and antagonist blocking (Fig. 5) , the 77 and antinociception. 76 REM sleep is enhanced by adenosine agonists in PnO of rat, 24 a reticular formation region that is homologous to the feline mPRF. Future functional studies are needed to determine the effects of pontine adenosine on antinociceptive behavior (?). Mu opioids in cat mPRF inhibit (↓) REM sleep 12 and have no effect (−) on antinociception. 76 Thus, although ACh, adenosine, and opioid receptors all are G protein coupled their actions on sleep and antinociception vary even within a single brain region. 
DISCUSSION
The primary finding of this study is that combined treatment with a selective adenosine A 1 receptor agonist (SPA) and a mu opioid agonist (DAMGO) caused partially additive G protein activation in brainstem nuclei known to regulate sleep and nociception. Second, these data are the first to demonstrate concentration dependent G protein activation by an adenosine A 1 receptor agonist in brainstem. The findings are discussed relative to evidence that adenosine plays a role in regulating arousal states and nociception. Mechanisms underlying additive responses and functional implications of additivity also are considered.
Adenosine as a modulator of sleep and nociception. Caffeine blocks adenosine A 1 receptors 42 and in humans caffeine consumption inhibits the electroencephalographic (EEG) and behavioral characteristics of slow-wave sleep. 43 Systemic administration of adenosine in cat 44 and dog 45 long has been known to have hypnotic effects. Preclinical studies showing enhancement of slow-wave sleep in rat led to the hypothesis that endogenous adenosine contributes to sleep regulation. 14 Adenosine agonists also cause EEG activity similar to EEG patterns produced by total sleep deprivation. 20 Sleep deprivation is accompanied by an increase in basal forebrain adenosine levels, 22, 23 and microdialysis delivery of adenosine into the LDT decreases wakefulness. 21 There is a compelling body of evidence that adenosine modulates sleep. 14, [16] [17] [18] [19] [20] 22, 24, 46 A sleep modulatory role for adenosine logically would involve brain regions and neurotransmitters known to regulate sleep. Figures 1 and 2 show adenosine A 1 receptor agonist activation of G proteins in sleep-related nuclei of the pons. The findings of G protein activation by an adenosine A 1 agonist (SPA) in PnC, PnO, DR, LDT, PPT, DMPAG, and VLPAG (Figs. 1, 2, 3 , and 5) are consistent with the role of adenosine as a sleep factor. Evidence reviewed in detail elsewhere shows that each of these brainstem regions plays a role in arousal state control. 29, 40 Cholinergic neurotransmission in PnC, PnO, LDT, and PPT activates G proteins 30 and contributes to sleep cycle control. [47] [48] [49] [50] [51] [52] These data concur with the possibility that adenosine modulates sleep by altering cholinergic neurotransmission in PnO, PnC, LDT, and PPT. 53 Figure 7 provides a schematic summary of currently available data showing the actions on antinociception and REM sleep when ACh, adenosine, and opioids are administered into the pontine reticular formation.
The midbrain periaqueductal gray plays a key role in nociception. 41 The present finding of enhanced G protein activation in DMPAG and VLPAG by agonists of mu opioid and adenosine A1 receptors (Figs. 1 and 3) is consistent with functional evidence for VLPAG regulation of sleep 54, 55 and mu opioid analgesia. 56 Differences between SPA-and DAMGO-induced activation of G proteins in dorsal and ventrolateral areas of PAG (Fig.  3 ) also are consistent with different spinal projections to distinct areas of PAG. 57, 58 Several clinical [59] [60] [61] and basic [62] [63] [64] [65] [66] studies show antinociceptive actions of adenosine and adenosine analogs. Receptors coupled to G proteins alter neuronal metabolism and excitability via effector proteins such as adenylate cyclase. In the dorsal horn of the spinal cord, the antinociceptive effects of adenosine have been linked to the inhibition of adenylyl cyclase. 67 SPA-induced G protein activation in rat brainstem is mediated by adenosine A 1 receptors. The hypothesis that activation of G proteins by SPA is receptor mediated is supported by the finding that the adenosine A 1 receptor antagonist (DPCPX) blocked SPA-induced [ 35 S]GTPγS binding (Fig. 5) . The hypothesis of receptor mediated G protein activation also is supported by data showing that the amount of G protein activation varied significantly as a function of adenosine A 1 agonist concentration. Fig. 6 shows that G protein activation by SPA reached its maximum level at 10 -5 M. Increases in SPA concentration up to 10 -3 M produced no further increase in G protein activation. Specific receptor binding saturates, or levels off, with increasing ligand concentrations whereas nonspecific binding does not saturate. 68 Thus, concentration dependence and saturation of a response indicate receptor mediation. The Figs. 5 and 6 results are consistent with significant G protein activation by adenosine in cerebellum, striatum, thalamus, hippocampus, and cerebral cortex 34 and medial geniculate body, superior colliculus, caudate-putamen, nucleus accumbens. 69 The present results extend these previous findings by demonstrating anatomically site specific, concentration dependent, SPA-induced, G protein activation in ponto-mesencephalic nuclei (Figs. 2 and 3) .
Endogenous adenosine and basal levels of [ 35 A. Non-Additive B. Fully Additive C. Fully Additive endogenous adenosine is responsible for a portion of basal G protein activation. 34, 69 Therefore, the present study sought to determine the extent to which endogenous adenosine contributed to basal levels of [ 35 Adenosine and opioid interactions: mechanisms, limitations, and conclusions. What mechanisms might account for the finding that simultaneous treatment with an adenosine A 1 agonist and a mu opioid agonist caused greater G protein activation than either agonist acting alone? The finding of partial additivity permits the inference that, in the brain regions studied, some mu opioid and adenosine A 1 receptors reside on the same neurons and activate some common G protein pools. 36, 37 Figure 8 schematizes receptor-G protein coupling patterns that might account, in part, for the data in Figs. 2 and 3 showing that combined treatment with SPA and DAMGO caused G protein activation that was greater than activation caused by SPA alone or DAMGO alone. Transmembrane signaling from receptor to G protein functions as a complex network rather than as a simple linear pathway. 70 Different receptors can converge on the same G protein pool, 71 or diverge to activate multiple G proteins. 70 When two different receptors activate the same pool of G proteins (Fig.  8A ) the sum of combined activation may not be greater than the sum of G proteins activated by each agonist alone (i.e., a nonadditive effect). G proteins can be activated in an additive manner when different receptors are coupled to different pools of G proteins on different neurons (Fig. 8B) or when different receptors activate multiple pools of G proteins in the same neuron (Fig.  8C ). The present findings show that combined treatment with an adenosine A 1 agonist and a mu agonist produced G protein activation that was partially additive. These data suggest that some adenosine A 1 and mu opioid receptors reside on the same neurons to activate common pools of G proteins (Fig. 8A) and that additional adenosine A 1 and mu opioid receptors activate independent G protein pools (Fig. 8B, 8C) .
The present data also showed that the amount of additivity was heterogeneous across brain regions (Fig. 4) . The greatest amount of additivity was observed in the pedunculopontine tegmental nucleus (PPT), and the least amount of additivity occurred in the dorsal raphe nucleus (DR). As schematized by Fig. 8 , the present data suggest that in the PPT, mu opioid and adenosine A 1 receptors mainly activate independent G protein pools. In contrast, mu opioid and A 1 receptors localized to the DR activate many common G protein systems.
Additional possible mechanisms accounting for the additive activation of G proteins by mu opioid and adenosine A 1 receptors include allosteric interactions and receptor dimerization. One important future approach will be to determine whether adenosine and opioid agonists can allosterically enhance the binding properties of their respective receptors in brainstem regions regulating nociception and sleep. Formation of complexes between two receptors, known as receptor dimerization, has been shown to occur for many different G protein coupled receptors. 72 Adenosine and dopamine receptors are known to form heterodimers, 73 and opioid receptor subtypes recently have been shown to form homodimers. 74 To the best of our knowledge, no information is available yet regarding the existence of adenosine A 1 and mu opioid receptor dimers, and this possibility remains an exciting area for future research. Functional consequences of receptor dimerization include an increased diversity of responses to drugs. 73 An understanding of the mechanisms by which opioids and adenosine interact could contribute to rational drug design.
In conclusion, the data presented here comprise the first report that, in PnO, PnC, DR, LDT, PPT, DMPAG, and VLPAG, simultaneous treatment with SPA and DAMGO causes significantly greater G protein activation than is caused by treatment with either agonist alone. The results encourage future functional studies of opioid and adenosine interactions in modulating the mutually exclusive relationship between nociception and sleep. 9, 75, 76 
